David Planchard
机构：Inserm, Université Paris-Saclay, Institut Gustave Roussy · ORCID：0000-0002-1565-8310
发表论文 926 篇 · 总被引 52678 次 · h-index 88
代表论文
- Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 83)
- Trastuzumab Deruxtecan for ERBB2 -Mutant Metastatic Non–Small Cell Lung Cancer With or Without Brain Metastases (2025 · JAMA Network Open · 被引 16)
- Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial (2025 · Journal of Thoracic Oncology · 被引 6)
- Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief Report (2025 · JTO Clinical and Research Reports · 被引 1)
- Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer (2026 · Clinical Cancer Research)
- Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial (2026 · The Lancet Oncology)